New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:55 EDTVSTM, VSTM, ONCY, ONCY, RIGL, RIGL, CELG, CELG, OXBT, OXBT, GALE, GALE, GTXI, GTXI, AFFY, AFFYBiotech Industry Organization to host a conference
15th Annual BIO CEO & Investor Conference is being held in New York on February 11-12.
News For CELG;OXBT;GALE;GTXI;AFFY;VSTM;ONCY;RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
09:20 EDTCELGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
07:16 EDTGTXIGTx enters into worldwide license agreement with UTRF
GTx, Inc. announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation, or UTRF, to develop its proprietary selective androgen receptor degrader technology which potentially can degrade and inhibit all forms of androgen receptor, including those resistant to current therapies, in patients with progressive castration-resistant prostate cancer.
April 21, 2015
14:38 EDTVSTMVerastem management to meet with Jefferies
Subscribe for More Information
09:34 EDTGALEGalena sent FDA warning letter following site inspection
A warning letter published by the FDA, dated April 3, states that the agency's inspection of Galena Biopharma's site in Portland, Oregon, conducted between November 17 and 21, 2014, revealed "serious violations" of FDAs PADE reporting requirements. Reference Link
April 20, 2015
06:36 EDTONCYOncolytics announces series of posters to be made at AACR Annual Meeting
Subscribe for More Information
April 17, 2015
06:31 EDTONCYOncolytics receives ODD by FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted an Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of malignant glioma. The company applied for an ODD for pediatric high grade gliomas, or HGG, however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages. In three previous brain cancer studies including gliomas, Reolysin has been shown to infect a variety of brain tumors when delivered intravenously.
April 16, 2015
09:14 EDTONCYOncolytics granted orphan status for malignant glioma treatment
The FDA granted Oncolytics orphan status for its treatment of malignant glioma, Reolysin. .
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
06:35 EDTONCYOncolytics Biotech's Reolysin shows positive results in pancreatic cancer
Subscribe for More Information
06:34 EDTONCYOncolytics Biotech presents Reolysin data at UK Immuno-oncology meeting
Oncolytics Biotech announced that Dr. Matt Coffey, COO, made a presentation titled "Reolysin and Immune Therapy: Rationale for Combination Therapy" at the Royal Society of Medicine's Immuno-oncology: Using the Body's Own Weapons conference, held in London, UK. The presentation included data from a single arm clinical study examining the use of Reolysin in combination with gemcitabine in patients with advanced pancreatic cancer, PD-1 and PD-L1 up regulation data from a single arm clinical study examining the use of Reolysin in patients with primary glioblastomas or brain metastases, as well as preclinical data. Highlights of new data presented include: Clinical evidence that Reolysin treatment results in immunological changes to both the tumor cells and the tumor microenvironment that is conducive to novel immune targeting interventions; and Updated results from the REO 017 study, in which pancreatic cancer patients received combination therapy with Reolysin and gemcitabine demonstrated a median overall survival of 10.2 months, and one- and two-year survival rates of 45% and 24%, respectively.
April 14, 2015
07:26 EDTGALEGalena completes over-enrollment of NeuVax Phase 3 PRESENT clinical trial
Galena Biopharma announced the completion of enrollment in the NeuVax Phase 3 PRESENT, or Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. As anticipated, Galena over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat, or ITT, population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment, or SPA, called for 700 patients; and, the company expects this higher number of ITT patients will increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a total of 141 events occur, whichever comes later.
April 13, 2015
17:25 EDTGTXIFormanek reports 5.1% passive stake in GTx
Subscribe for More Information
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use